# Domain Associates

> Domain Associates is a VC fund backing Biotechnology and Health Care. See 196 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Diego, United States
- Total investments: 196
- Last investment: Apr 2023
- Lead investor: 16%
- Fund size: $164M
- Last fund: Dec 2016
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/domain-associates
- X (Twitter): http://twitter.com/domainvc
- Website: http://www.domainvc.com

Domain Associates is a VC fund in San Diego focused on Biotechnology and Health Care. Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

## Contacts

5 contacts available for Domain Associates. Shizune tracks 9 team members at Domain Associates. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/domain-associates?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.8M–$50M |
| Series B | $10M–$60M |
| Series C | $10M–$57M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 82 | 42% |
| Health Care | 76 | 39% |
| Medical | 46 | 23% |
| Pharmaceutical | 33 | 17% |
| Therapeutics | 26 | 13% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 44 | 22% |
| Series C | 38 | 19% |
| Series A | 33 | 17% |
| Series D | 20 | 10% |
| Funding Round | 16 | 8% |

14 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 100 | 51% |
| Canada | 2 | 1% |
| Estonia | 1 | 1% |
| Ireland | 1 | 1% |
| Hong Kong | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brian Dovey | Partner | 7 | https://shizune.co/investors/profile/brian-dovey |
| Brian Halak | Partner | 18 | https://shizune.co/investors/profile/brian-k-halak |
| Dennis Podlesak | Venture Capitalist | 5 | https://shizune.co/investors/profile/dennis-podlesak |
| Eckard Weber | Partner | 8 | https://shizune.co/investors/profile/eckard-weber |
| Jesse I. Treu | Founding Partner | 13 | https://shizune.co/investors/profile/jesse-i-treu |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M | Series G | Apr 14, 2023 |  |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. |  | Series F | Aug 15, 2022 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M | Series B | Nov 03, 2021 |  |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M | Series C | Oct 13, 2021 |  |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M | Series C | Oct 13, 2021 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $96M | Series B | Apr 12, 2021 |  |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $55M | Series E | Aug 06, 2020 |  |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $55M | Series E | Aug 06, 2020 |  |
| Nobias Therapeutics | Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier. | $3.8M | Series A | Jul 24, 2020 |  |
| Exalys Therapeutics | Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options.Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor healthoutcomes. | $15M | Series A | Jul 16, 2020 |  |

10 of 196 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 23 deals together
- [Montreux Equity Partners](https://shizune.co/investors/profile/montreaux-equity-partners) — VC Fund, 20 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 19 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 16 deals together
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund, 15 deals together
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 12 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Specialist VC](https://shizune.co/investors/profile/united-angels-vc) — VC Fund
- [Superangel](https://shizune.co/investors/profile/superangel) — VC Fund
- [Tera Ventures](https://shizune.co/investors/profile/tera-ventures) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Medical VC Funds in United States](https://shizune.co/investors/medical-vc-funds-united-states)
- [Medical Investors](https://shizune.co/investors/medical-investors)
- [Medical VC Funds](https://shizune.co/investors/medical-vc-funds)
- [Biotechnology Investors in Estonia](https://shizune.co/investors/biotechnology-investors-estonia)

## FAQ

### What does Domain Associates invest in?

Domain Associates invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 196 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Domain Associates's check size?

Domain Associates typically joins rounds of $3.8M–$50M at Series A, $10M–$60M at Series B and $10M–$57M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Domain Associates participates in.

### How do I contact Domain Associates?

Public channels for Domain Associates include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Domain Associates?

The team at Domain Associates includes Brian Dovey (Partner), Brian Halak (Partner) and Dennis Podlesak (Venture Capitalist), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co